Literature DB >> 24945159

Prediction of acute respiratory disease in current and former smokers with and without COPD.

Russell P Bowler1, Victor Kim2, Elizabeth Regan3, André A A Williams3, Stephanie A Santorico4, Barry J Make3, David A Lynch3, John E Hokanson5, George R Washko6, Peter Bercz2, Xavier Soler7, Nathaniel Marchetti2, Gerard J Criner2, Joe Ramsdell7, MeiLan K Han8, Dawn Demeo6, Antonio Anzueto9, Alejandro Comellas10, James D Crapo3, Mark Dransfield11, J Michael Wells11, Craig P Hersh6, Neil MacIntyre12, Fernando Martinez8, Hrudaya P Nath11, Dennis Niewoehner13, Frank Sciurba14, Amir Sharafkhaneh15, Edwin K Silverman6, Edwin J R van Beek16, Carla Wilson17, Christine Wendt13, Robert A Wise18.   

Abstract

BACKGROUND: The risk factors for acute episodes of respiratory disease in current and former smokers who do not have COPD are unknown.
METHODS: Eight thousand two hundred forty-six non-Hispanic white and black current and former smokers in the Genetic Epidemiology of COPD (COPDGene) cohort had longitudinal follow-up (LFU) every 6 months to determine acute respiratory episodes requiring antibiotics or systemic corticosteroids, an ED visit, or hospitalization. Negative binomial regression was used to determine the factors associated with acute respiratory episodes. A Cox proportional hazards model was used to determine adjusted hazard ratios (HRs) for time to first episode and an acute episode of respiratory disease risk score.
RESULTS: At enrollment, 4,442 subjects did not have COPD, 658 had mild COPD, and 3,146 had moderate or worse COPD. Nine thousand three hundred three acute episodes of respiratory disease and 2,707 hospitalizations were reported in LFU (3,044 acute episodes of respiratory disease and 827 hospitalizations in those without COPD). Major predictors included acute episodes of respiratory disease in year prior to enrollment (HR, 1.20; 95% CI, 1.15-1.24 per exacerbation), airflow obstruction (HR, 0.94; 95% CI, 0.91-0.96 per 10% change in % predicted FEV1), and poor health-related quality of life (HR, 1.07; 95% CI, 1.06-1.08 for each 4-unit increase in St. George's Respiratory Questionnaire score). Risks were similar for those with and without COPD.
CONCLUSIONS: Although acute episode of respiratory disease rates are higher in subjects with COPD, risk factors are similar, and at a population level, there are more episodes in smokers without COPD.

Entities:  

Mesh:

Year:  2014        PMID: 24945159      PMCID: PMC4188150          DOI: 10.1378/chest.13-2946

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  38 in total

1.  Mortality after an emergency department visit for exacerbation of chronic obstructive pulmonary disease.

Authors:  Sunghye Kim; Sunday Clark; Carlos A Camargo
Journal:  COPD       Date:  2006-06       Impact factor: 2.409

2.  Racial differences in quality of life in patients with COPD.

Authors:  MeiLan K Han; Douglas Curran-Everett; Mark T Dransfield; Gerard J Criner; Lening Zhang; James R Murphy; Nadia N Hansel; Dawn L DeMeo; Nicola A Hanania; Elizabeth A Regan; Barry J Make; Fernando J Martinez; Gloria E Westney; Marilyn G Foreman
Journal:  Chest       Date:  2011-06-02       Impact factor: 9.410

3.  Effect of cimetidine on the gastric bacterial flora.

Authors:  W S Ruddell; A T Axon; J M Findlay; B A Bartholomew; M J Hill
Journal:  Lancet       Date:  1980-03-29       Impact factor: 79.321

4.  Pulmonary arterial enlargement and acute exacerbations of COPD.

Authors:  J Michael Wells; George R Washko; MeiLan K Han; Naseer Abbas; Hrudaya Nath; A James Mamary; Elizabeth Regan; William C Bailey; Fernando J Martinez; Elizabeth Westfall; Terri H Beaty; Douglas Curran-Everett; Jeffrey L Curtis; John E Hokanson; David A Lynch; Barry J Make; James D Crapo; Edwin K Silverman; Russell P Bowler; Mark T Dransfield
Journal:  N Engl J Med       Date:  2012-09-03       Impact factor: 91.245

5.  The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study.

Authors:  Victor Kim; MeiLan K Han; Gwendolyn B Vance; Barry J Make; John D Newell; John E Hokanson; Craig P Hersh; Douglas Stinson; Edwin K Silverman; Gerard J Criner
Journal:  Chest       Date:  2011-04-07       Impact factor: 9.410

6.  Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease.

Authors:  Mark T Dransfield; Jennifer J Davis; Lynn B Gerald; William C Bailey
Journal:  Respir Med       Date:  2005-10-19       Impact factor: 3.415

7.  A predictive model of hospitalisation and death from chronic obstructive pulmonary disease.

Authors:  Stuart Schembri; William Anderson; Steve Morant; Janet Winter; Philip Thompson; Daniel Pettitt; Thomas M MacDonald; John H Winter
Journal:  Respir Med       Date:  2009-06-09       Impact factor: 3.415

8.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 9.  Association between gastroesophageal reflux and sinusitis, otitis media, and laryngeal malignancy: a systematic review of the evidence.

Authors:  Edward M Weaver
Journal:  Am J Med       Date:  2003-08-18       Impact factor: 4.965

10.  Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD.

Authors:  Karin H Groenewegen; Annemie M W J Schols; Emiel F M Wouters
Journal:  Chest       Date:  2003-08       Impact factor: 9.410

View more
  48 in total

1.  Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.

Authors:  Prescott G Woodruff; R Graham Barr; Eugene Bleecker; Stephanie A Christenson; David Couper; Jeffrey L Curtis; Natalia A Gouskova; Nadia N Hansel; Eric A Hoffman; Richard E Kanner; Eric Kleerup; Stephen C Lazarus; Fernando J Martinez; Robert Paine; Stephen Rennard; Donald P Tashkin; MeiLan K Han
Journal:  N Engl J Med       Date:  2016-05-12       Impact factor: 91.245

Review 2.  Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study.

Authors:  Diego J Maselli; Surya P Bhatt; Antonio Anzueto; Russell P Bowler; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Ashraf Fawzy; Marilyn G Foreman; Nicola A Hanania; Craig P Hersh; Victor Kim; Gregory L Kinney; Nirupama Putcha; Emily S Wan; J Michael Wells; Gloria E Westney; Kendra A Young; Edwin K Silverman; MeiLan K Han; Barry J Make
Journal:  Chest       Date:  2019-05-30       Impact factor: 9.410

3.  β2 adrenergic receptor polymorphisms and COPD exacerbations: a complicated story.

Authors:  Wassim W Labaki; MeiLan K Han
Journal:  Thorax       Date:  2019-09-03       Impact factor: 9.139

4.  Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults.

Authors:  Diane R Gold; Augusto A Litonjua; Vincent J Carey; JoAnn E Manson; Julie E Buring; I-Min Lee; David Gordon; Joseph Walter; Georgina Friedenberg; John L Hankinson; Trisha Copeland; Heike Luttmann-Gibson
Journal:  Contemp Clin Trials       Date:  2016-01-16       Impact factor: 2.226

5.  Association between acute respiratory disease events and the MUC5B promoter polymorphism in smokers.

Authors:  Samuel Y Ash; Rola Harmouche; Rachel K Putman; James C Ross; Fernando J Martinez; Augustine M Choi; Russell P Bowler; Elizabeth A Regan; Jeffrey L Curtis; MeiLan K Han; Richard C Boucher; Wanda K O'Neal; Hiroto Hatabu; David A Lynch; Ivan O Rosas; Gary M Hunninghake; Raul San Jose Estepar; George R Washko
Journal:  Thorax       Date:  2018-02-13       Impact factor: 9.139

6.  Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.

Authors:  Mark T Dransfield; Ken M Kunisaki; Matthew J Strand; Antonio Anzueto; Surya P Bhatt; Russell P Bowler; Gerard J Criner; Jeffrey L Curtis; Nicola A Hanania; Hrudaya Nath; Nirupama Putcha; Sarah E Roark; Emily S Wan; George R Washko; J Michael Wells; Christine H Wendt; Barry J Make
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

7.  A ferret model of COPD-related chronic bronchitis.

Authors:  S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe
Journal:  JCI Insight       Date:  2016-09-22

8.  Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.

Authors:  Augustine Tee; Wai Leng Chow; Colin Burke; Basavarajaiah Guruprasad
Journal:  Singapore Med J       Date:  2018-03-16       Impact factor: 1.858

9.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.

Authors:  Jason D Keene; Sean Jacobson; Katerina Kechris; Gregory L Kinney; Marilyn G Foreman; Claire M Doerschuk; Barry J Make; Jeffrey L Curtis; Stephen I Rennard; R Graham Barr; Eugene R Bleecker; Richard E Kanner; Eric C Kleerup; Nadia N Hansel; Prescott G Woodruff; MeiLan K Han; Robert Paine; Fernando J Martinez; Russell P Bowler; Wanda K O'Neal
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

10.  Lung Mass in Smokers.

Authors:  George R Washko; Gregory L Kinney; James C Ross; Raúl San José Estépar; MeiLan K Han; Mark T Dransfield; Victor Kim; Hiroto Hatabu; Carolyn E Come; Russell P Bowler; Edwin K Silverman; James Crapo; David A Lynch; John Hokanson; Alejandro A Diaz
Journal:  Acad Radiol       Date:  2016-12-08       Impact factor: 3.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.